• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Dr Jeremy Chataway - Articles and news items

Apitope’s Phase II multiple sclerosis trial a success

Industry news / 22 February 2017 / Niamh Marriott, Digital Editor

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study evaluated the effects of ATX-MS-1467 in 19 patients with […]